In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Heron Therapeutics, Inc.. Trade Record

NASDAQ:HRTX Heron Therapeutics, Inc. stock gains 34.34% Exit Jan 30, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart HRTX Dec 18, 2017, priceSeries
About Heron Therapeutics, Inc.

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company's lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
90.61
Entry Date
Dec 18, 2017
Entry Price
17.00
Sell Date
Jan 30, 2018
Sell Price
22.84
Net Gain
34.34%
Hold Time
28 Trading Days